Chronic kidney disease (CKD) is a global scourge affecting hundreds of millions, often leading to dialysis. Current treatments can slow damage, but approved drugs that directly restore kidney function remain as elusive as a polite internet comment section. Researchers at Tohoku University Graduate School of Medicine have now stumbled upon an unexpected candidate: lubiprostone, a drug long used to treat constipation.
In a clinical trial, the medication appeared to slow the decline of kidney function in patients with moderate CKD, raising hopes for a whole new approach. “We noticed that constipation is a symptom that often accompanies CKD, and decided to investigate this link further,” explains study lead Abe. Essentially, constipation disrupts the intestinal microbiota, worsening kidney function. Working backwards, the team hypothesized that treating constipation could improve kidney function.
The study, the multicenter Phase II LUBI-CKD TRIAL across nine Japanese medical institutions, enrolled 150 patients with moderate CKD. Participants received either lubiprostone (8 µg or 16 µg doses) or a placebo. Results surprised researchers: both doses showed a slower decline in kidney function compared with placebo, measured by estimated glomerular filtration rate (eGFR). The effect appeared dose-dependent, with the 16 µg group showing particularly promising preservation over the 24-week trial period.
Scientists then dug into the why. Analysis pointed to changes in the gut microbiome: lubiprostone increased spermidine production, a compound tied to healthier mitochondrial activity - the power plants of cells. Improved mitochondrial function may shield kidney tissue from further damage. Interestingly, the treatment didn't significantly reduce certain uremic toxins as expected; benefits seemed tied more to microbiome remodeling and mitochondrial support, which could reshape CKD treatment thinking.
Because lubiprostone is already approved for chronic constipation, future clinical use could be faster than developing a new drug from scratch. Researchers also believe the discovery may have implications beyond kidney disease, as mitochondrial dysfunction is involved in many chronic illnesses. The team is now planning larger Phase 3 trials and searching for biomarkers to predict treatment response. For people with CKD, even modest slowing of kidney decline could potentially delay dialysis and improve quality of life - proving once again that sometimes, the path to healing runs through the gut.